And loving start-ups like - Business Finland

...and loving start-ups like

Novartis Finland works hard to build bridge between HQ & Finland
Health Ecosystem; targeted visits to Basel started in 2014 when
Finland Science Delegation made a successful visit:

                                   3

2018 Business Finland organized Business Delegation visit to Basel
to meet Novartis (and Roche); several collaborations got started...

• Finnish Business Delegation in Basel HQ Sep 2018
• Theme at Novartis: Go Big in Data and Digital
• 30+ Finnish companies including Precordior
• Minister Saarikko and key public stakeholders
• Health and innovation policy discussions with NVS senior
  management
• 1on1 discussions between companies and NVS leaders         Novartis Chairman Dr. Jörg
                                                             Reinhardt in Go Big in Data
                                                             & Digital meeting

Finland is well on Novartis Venture Funds’ radar too:
2 portfolio companies from Finland (0 from other Nordic countries)
Forendo Pharma and Rappta Therapeutics (released on Oct 13, 2020)

2019 Rana Lonnen, NVS Head S&E Strategic Venture Capital, BD&L
Capital Venture Fund came to Slush to celebrate 2 deals from 2018
campus visit...

Let’s keep in touch:
Tatu Laurila
+358 40 564 3024
tatu.Laurila@novartis.com

Instant heart monitoring
 with your smartphone!

Precordior’s Solution
Saving lives - Detect cardiac diseases with your
smartphone

Application records micro-motions of chest for 60
seconds using the built-in motion sensors of your
smartphone

A new way for doctors and consumers to detect
 ● Atrial Fibrillation
 ● Coronary Artery Disease
 ● Heart Failure

No accessories required!

Precordior Product Portfolio Status
           Atrial       On the market in the EU. Class IIa medical device.
        Fibrillation    FDA 510(k) clearance process in progress. Expected to be completed by Jan 2021.

       Heart Failure    Research in progress in Finland and USA.
        Detection       Expected completion by the end of Q2 2021.

       Heart Failure    Research in progress in Finland and USA.
        Follow-up       Expected completion by the end of Q2 2021.

      Coronary Artery   Research in progress in Finland.
          Disease       Fully completed study 2021
         Detection

The Core of Collaboration: The Endgame is the Same

     Healthcare in 4D:                                               Business insights in multiple markets
     Better care for our patients by
                                                                          •   Providers
     •   Drugs                                                            •   Payors
     •   Diagnosis                                                        •   Key opinion leaders
     •   Digital (/data)                                                  •   Patient journey / engagement
     •   Devices
                                                                          Optimal market launch to build on
                Companion diagnostics, precision medicine,
                digital therapeutics etc.

“Healthcare is a challenging ecosystem with multiple stakeholders influencing on the outcome. Our collaboration
with Novartis originated in 2018 with Novartis Finland, now encompassing a global reach in the cardiovascular field.
We envision a holistic future of healthcare where better health is a combination of pharmaceuticals, technology and
people themselves in the focus. In this journey joining forces with Novartis has provided us an exceptional
opportunity to fulfil this vision - Together.“
                                                             -Juuso Blomster, MD, PhD, CEO Precordior Ltd

Juuso Blomster, MD Cardiologist
         Chief Executive Officer
          Tel. +358 50 310 0194
E-mail: juuso.blomster@precordior.com

        www.precordior.com
        www.cardiosignal.com